Bb Biotech Ag Stake in Halozyme Therapeutics (HALO) Has Cut as Market Value Declined; Orbimed Advisors Holding in Bristol Myers Squibb Co (BMY) Boosted as Market Valuation Rose

May 18, 2018 - By Stephen Andrade

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Logo

Bb Biotech Ag decreased its stake in Halozyme Therapeutics Inc. (HALO) by 1.23% based on its latest 2017Q4 regulatory filing with the SEC. Bb Biotech Ag sold 105,914 shares as the company’s stock declined 6.13% with the market. The institutional investor held 8.52M shares of the health care company at the end of 2017Q4, valued at $172.62 million, down from 8.63 million at the end of the previous reported quarter. Bb Biotech Ag who had been investing in Halozyme Therapeutics Inc. for a number of months, seems to be less bullish one the $2.62 billion market cap company. The stock decreased 1.77% or $0.33 during the last trading session, reaching $18.29. About 1.15M shares traded or 22.04% up from the average. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 32.10% since May 18, 2017 and is uptrending. It has outperformed by 20.55% the S&P500.

Samuel Isaly increased its stake in Bristol Myers Squibb Co (BMY) by 358.67% based on its latest 2017Q4 regulatory filing with the SEC. Orbimed Advisors Llc bought 538,000 shares as the company’s stock rose 2.38% while stock markets declined. The hedge fund run by Samuel Isaly held 688,000 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $42.16M, up from 150,000 at the end of the previous reported quarter. Orbimed Advisors Llc who had been investing in Bristol Myers Squibb Co for a number of months, seems to be bullish on the $86.23B market cap company. The stock increased 1.02% or $0.53 during the last trading session, reaching $52.74. About 8.10M shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has risen 11.37% since May 18, 2017 and is uptrending. It has underperformed by 0.18% the S&P500.

Bb Biotech Ag, which manages about $3.55 billion US Long portfolio, upped its stake in Five Prime Therapeutics Inc. (NASDAQ:FPRX) by 50,000 shares to 827,500 shares, valued at $18.14M in 2017Q4, according to the filing. It also increased its holding in Tesaro Inc. (NASDAQ:TSRO) by 50,000 shares in the quarter, for a total of 1.05M shares, and has risen its stake in Ionis Pharmaceuticals Inc..

Investors sentiment increased to 1.66 in 2017 Q4. Its up 0.40, from 1.26 in 2017Q3. It is positive, as 13 investors sold HALO shares while 45 reduced holdings. 39 funds opened positions while 57 raised stakes. 118.31 million shares or 0.18% less from 118.53 million shares in 2017Q3 were reported. Brown Advisory owns 151,447 shares. Synovus Fincl reported 0.01% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). California Employees Retirement, California-based fund reported 204,800 shares. Rhumbline Advisers owns 126,811 shares. Price T Rowe Assoc Md stated it has 45,378 shares. 19,045 were reported by Virtu Fincl Limited Liability Co. Lombard Odier Asset Mgmt (Switzerland) Sa has invested 0.64% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Kennedy Mngmt holds 0.18% or 507,978 shares. Manufacturers Life Insur The invested in 0.02% or 716,482 shares. Paradigm Capital Mngmt New York stated it has 0.02% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Fisher Asset Management Limited Co holds 0.01% in Halozyme Therapeutics, Inc. (NASDAQ:HALO) or 560,373 shares. Timpani Cap Mngmt Limited Liability Corporation has 1.13% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Numeric Invsts Ltd Liability Company invested in 12,200 shares. Creative Planning owns 87,682 shares. Comml Bank Of Mellon Corporation stated it has 1.86 million shares.

Analysts await Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report earnings on August, 14. They expect $-0.21 EPS, up 8.70% or $0.02 from last year’s $-0.23 per share. After $-0.19 actual EPS reported by Halozyme Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 10.53% negative EPS growth.

Among 10 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 6 have Buy rating, 1 Sell and 3 Hold. Therefore 60% are positive. Halozyme Therapeutics had 26 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Market Outperform” rating by JMP Securities given on Tuesday, August 11. The firm has “Market Outperform” rating by JMP Securities given on Wednesday, March 9. Barclays Capital maintained it with “Overweight” rating and $16 target in Wednesday, February 24 report. As per Wednesday, November 8, the company rating was maintained by Canaccord Genuity. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) has “Hold” rating given on Wednesday, November 22 by Barclays Capital. Barclays Capital downgraded the stock to “Underweight” rating in Friday, May 11 report. Citigroup downgraded the stock to “Neutral” rating in Friday, January 6 report. Piper Jaffray maintained it with “Buy” rating and $2000 target in Wednesday, August 9 report. The rating was maintained by Piper Jaffray on Friday, September 16 with “Overweight”. Canaccord Genuity maintained it with “Buy” rating and $21.0 target in Wednesday, February 21 report.

More news for Halozyme Therapeutics, Inc. (NASDAQ:HALO) were recently published by: Seekingalpha.com, which released: “Premarket analyst action – healthcare” on May 11, 2018. Benzinga.com‘s article titled: “38 Stocks Moving In Friday’s Mid-Day Session” and published on May 11, 2018 is yet another important article.

Investors sentiment decreased to 0.94 in 2017 Q4. Its down 0.09, from 1.03 in 2017Q3. It fall, as 72 investors sold BMY shares while 526 reduced holdings. 106 funds opened positions while 457 raised stakes. 1.11 billion shares or 0.48% more from 1.11 billion shares in 2017Q3 were reported. Boston Family Office Ltd Liability Company holds 42,352 shares or 0.28% of its portfolio. 3,190 were reported by Plante Moran Financial Advisors Lc. Amundi Pioneer Asset Management holds 0.26% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 2.80M shares. Lenox Wealth Management holds 1,528 shares or 0.03% of its portfolio. Regent Limited Co holds 0.51% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 25,252 shares. Oarsman owns 3,750 shares or 0.1% of their US portfolio. Canada Pension Plan Board invested 0.55% in Bristol-Myers Squibb Company (NYSE:BMY). Avalon Asset Mngmt Ltd Liability has invested 1.8% in Bristol-Myers Squibb Company (NYSE:BMY). Terril Brothers holds 9.54% or 505,594 shares. Lbmc Invest Advsr has invested 0.07% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Envestnet Asset Management Inc holds 92,673 shares. Bonness Enterp Inc stated it has 2.25% in Bristol-Myers Squibb Company (NYSE:BMY). State Treasurer State Of Michigan invested in 746,517 shares or 0.36% of the stock. Ftb Advisors accumulated 12,170 shares. Sfmg Limited Company invested 0.07% in Bristol-Myers Squibb Company (NYSE:BMY).

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Fool.com which released: “Why Bristol-Myers Squibb Stock Crashed in April” on May 09, 2018, also Streetinsider.com with their article: “Bristol-Myers (BMY) option implied volatility flat, to present immuno-oncology-based research at ASCO” published on May 17, 2018, Bizjournals.com published: “How Bristol-Myers Squibb’s new Peninsula digs boost its battle to beat cancer” on May 01, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Seekingalpha.com and their article: “Don’t Buy L Brands – Cramer’s Lightning Round (5/15/18)” published on May 16, 2018 as well as Seekingalpha.com‘s news article titled: “Jounce down 32% premarket on announcement of trial data on lead candidate JTX-2011” with publication date: May 17, 2018.

Orbimed Advisors Llc, which manages about $6.70B and $7.91 billion US Long portfolio, decreased its stake in Galapagos Nv by 36,800 shares to 486,990 shares, valued at $45.66M in 2017Q4, according to the filing. It also reduced its holding in Wright Med Group N V by 2.09M shares in the quarter, leaving it with 6.85M shares, and cut its stake in Ironwood Pharmaceuticals Inc (Call) (NASDAQ:IRWD).

Since December 12, 2017, it had 2 insider buys, and 1 sale for $163,963 activity. Samuels Theodore R. II bought $249,187 worth of stock. Paliwal Dinesh C had bought 4,770 shares worth $249,948 on Monday, April 30.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: